Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares

Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton sold 25,107 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $0.56, for a total transaction of $14,059.92. Following the completion of the sale, the chief executive officer now owns 242,591 shares in the company, valued at $135,850.96. This represents a 9.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Athira Pharma Stock Performance

Athira Pharma stock opened at $0.57 on Friday. The business’s fifty day moving average is $0.61 and its two-hundred day moving average is $1.50. The firm has a market cap of $22.16 million, a P/E ratio of -0.20 and a beta of 2.99. Athira Pharma, Inc. has a 52 week low of $0.41 and a 52 week high of $4.30.

Athira Pharma (NASDAQ:ATHA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.05. On average, equities research analysts predict that Athira Pharma, Inc. will post -2.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Mizuho lowered shares of Athira Pharma from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $5.00 to $0.50 in a research report on Thursday, September 19th.

Institutional Trading of Athira Pharma

Several hedge funds have recently modified their holdings of ATHA. Rothschild Investment LLC acquired a new position in Athira Pharma during the 2nd quarter worth $34,000. XTX Topco Ltd bought a new stake in shares of Athira Pharma during the second quarter worth $60,000. Invst LLC acquired a new position in shares of Athira Pharma during the second quarter valued at $68,000. American Century Companies Inc. boosted its holdings in Athira Pharma by 9.4% in the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after acquiring an additional 3,333 shares during the last quarter. Finally, Forefront Analytics LLC increased its position in Athira Pharma by 126.0% in the second quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after purchasing an additional 25,979 shares during the period. 57.12% of the stock is owned by institutional investors.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.